In January 2012, the CCSG-supported Genomics and DNA Analysis facilities consolidated their activities to form a comprehensive institutional genomics shared resource: the Sequencing and Microarray Facility (SMF). The mission of the SMF is to support genomics research at MD Anderson by providing investigators with access to state-of-the-art instrumentation and a high level of technical expertise in a centralized facility, thereby minimizing the duplication of expensive equipment while maintaining technical excellence. The SMF, located in a newly renovated 1600-square-foot laboratory space, provides a complete range of genomic services that includes project and technology consultation, RNA and DNA quality assessment and quantification, Sanger DNA sequencing, comprehensive lllumina next-generation sequencing services, gene resequencing, fluorescent fragment analysis, and TaqMan-based gene expression analysis. The SMF also provides complete DNA and RNA services for several microarray applications, including gene expression, single-nucleotide polymorphism, comparative genomic hybridization, chromatin immunoprecipitation microarrays, and microRNA profiling. MD Anderson has demonstrated its support and commitment to the SMF by providing more than $1.2 million in funding for the purchase of state-of-the-art instrumentation. Major equipment includes AB 3730 sequencers, lllumina Hiseq2000 sequencers, an AB 7900 Sequence Detection System, Affymetrix GeneChip systems, an Axon Genepix 4000B Scanner, a MAUI Hybridization System, and an lllumina BeadXpress and iScan. Since 2008, the SMF component facilities processed 785,638 samples for 399 Pis in 19 CCSG programs supporting 14 P01, 227 R01, and 14 SPORE grants. The total number of samples processed increased 39%, and the number of Pis using the SMF increased 32% over the previous grant period (3/1/02-2/28/07). Publications cited using the SMF have appeared in several high impact journals including Nat Genet, Lancet Oncol, Cell and Cancer Cell. Peer-reviewed Pis accounted for 96% of the samples processed. Funding for the new grant cycle is proposed to come from the CCSG (22%), user fees (77.8%) and institutional support (0.2%). Future plans include the expansion of the NGS service to include platforms for midscale and single-molecule sequencing. The SMF will continue to expand the range of NGS and validation services offered and develop methods that can successfully use MD Anderson's unique resource of archival tumor samples

Public Health Relevance

The SMF is the primary sequencing and microarray facility of MD Anderson. The SMF provides essential genomic analysis services to support cancer center members in basic science, translational, and population based research programs. Addition of essential whole genome and whole transcriptome sequencing services has enabled researchers to do more exploratory biomarker experiments.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Daver, Naval; Verstovsek, Srdan (2015) Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosis. Leuk Lymphoma 56:279-80
Burstein, Matthew D; Tsimelzon, Anna; Poage, Graham M et al. (2015) Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res 21:1688-98
Mersch, Jacqueline; Jackson, Michelle A; Park, Minjeong et al. (2015) Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 121:269-75
Pugh, Thomas J; Mahmood, Usama; Swanson, David A et al. (2015) Sexual potency preservation and quality of life after prostate brachytherapy and low-dose tadalafil. Brachytherapy 14:160-5
Zuo, Zhuang; Maiti, Sourindra; Hu, Shimin et al. (2015) Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Mod Pathol 28:373-82
Martin, Neil E; Massey, Laura; Stowell, Caleb et al. (2015) Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol 67:460-7
Shen, Qi; Ouyang, Juan; Tang, Guilin et al. (2015) Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. Eur J Haematol 95:168-76
Massarweh, Nader N; Haynes, Alex B; Chiang, Yi-Ju et al. (2015) Adequacy of the National Quality Forum's Colon Cancer Adjuvant Chemotherapy Quality Metric: Is 4 Months Soon Enough? Ann Surg 262:312-20
Garcia-Manero, Guillermo; Khoury, Hanna J; Jabbour, Elias et al. (2015) A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin Cancer Res 21:985-94
Brown, Alaina J; Sun, Charlotte C; Urbauer, Diana et al. (2015) Targeting those with decreased meaning and peace: a supportive care opportunity. Support Care Cancer 23:2025-32

Showing the most recent 10 out of 2114 publications